Personalized treatment study for acute myeloid leukemia
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This study matches people with acute myeloid leukemia (AML) to treatments based on their specific genetic markers. It aims to find the most effective therapy with fewer side effects compared to standard care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older and have been diagnosed with AML, or are 60+ with certain genetic changes.
- You have not had prior chemotherapy for AML, except for hydroxyurea to control white blood cell counts.
- Your kidneys and liver are functioning adequately (confirmed by blood tests).
- You are generally able to care for yourself (ECOG score 0-2).
- You do not have acute promyelocytic leukemia (APL) or active leukemia in the brain or spinal cord.
- You are willing to provide written informed consent and follow the study procedures.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing new drug combinations for people with newly diagnosed, high-risk AML who have not yet started treatment. It aims to find more effective therapies for this aggressive form of leukemia.
This study tests a personalized approach to treating acute myeloid leukemia (AML) that has come back or stopped responding to prior treatments. Researchers will analyze your leukemia cells in the lab to find the best drug combination for your specific cancer, with the goal of improving treatment outcomes.
This study screens people with newly suspected acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) to see which treatment approach fits best—either a specific study treatment or standard care. It may help by directing you to the right option and by sharing your blood/bone marrow samples for research.
This trial tests a combination treatment (chemo drugs plus a growth-factor medicine) for people newly diagnosed with acute myeloid leukemia (AML) or certain high-risk myelodysplastic syndromes (MDS). It may help by targeting cancer cells in the blood and bone marrow and improving remission chances.
This trial tests new treatment options for people whose acute myeloid leukemia (AML) has either not responded to standard therapy or returned. It aims to find better ways to help those who need new options.
This trial tests a combination of chemotherapy drugs (venetoclax, cladribine, cytarabine, and azacitidine) for people newly diagnosed with specific types of acute myeloid leukemia (AML) who cannot have or choose not to have standard intensive chemotherapy.
Hear when a new Previously Untreated Relapsed Refractory Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.